# A Study of LP-168 in Healthy Volunteers

> **NCT05432713** · PHASE1 · COMPLETED · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 70 (actual)

## Conditions studied

- Multiple Sclerosis
- NMO Spectrum Disorder

## Interventions

- **DRUG:** LP-168 tablet
- **DRUG:** LP-168 Placebo tablet

## Key facts

- **NCT ID:** NCT05432713
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-14
- **Primary completion:** 2022-11-20
- **Final completion:** 2022-12-28
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432713, "A Study of LP-168 in Healthy Volunteers". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05432713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*